Compare · QSI vs TMO
QSI vs TMO
Side-by-side comparison of Quantum-Si Incorporated (QSI) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both QSI and TMO operate in Industrial Machinery/Components (Industrials), so they compete in similar markets.
- TMO is the larger of the two at $257.53B, about 898.1x QSI ($286.7M).
- Over the past year, QSI is down 56.9% and TMO is up 26.8% - TMO leads by 83.8 points.
- QSI has been more active in the news (7 items in the past 4 weeks vs 6 for TMO).
- TMO has more recent analyst coverage (25 ratings vs 4 for QSI).
- Company
- Quantum-Si Incorporated
- Thermo Fisher Scientific Inc
- Price
- $1.11-14.56%
- $690.13-0.92%
- Market cap
- $286.7M
- $257.53B
- 1M return
- +43.70%
- +4.77%
- 1Y return
- -56.95%
- +26.83%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 7
- 6
- Recent ratings
- 4
- 25
Quantum-Si Incorporated
Quantum-Si incorporated operates first next-generation protein sequencing and genomics platform for healthcare industries. It offers a single molecule detection solution to decode the molecules of life, including sample preparation, single molecule, massively parallel, and protein identification. The company's technology has the applications in proteomics, single cell, transcriptomics, genomics, metabolomics, and drug testing and screening fields. The company is based in Guilford, Connecticut. Quantum-Si incorporated is a subsidiary of 4Catalyzer Corporation.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest QSI
- Quantum-Si to Provide a Business Update and Report Third Quarter 2026 Financial Results on November 5, 2026
- SEC Form 8-K filed by Quantum-Si Incorporated
- Quantum-Si Regains Compliance with Nasdaq Minimum Bid Price Requirement
- SEC Form 8-K filed by Quantum-Si Incorporated
- Quantum-Si Demonstrates Detection of 19 Amino Acids in Proteus™ Development Program
- Quantum-Si Incorporated filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Quantum-Si Presents Interim Proteus™ Data at World HUPO 2026 Demonstrating a Significant Step Change in Performance Compared to Platinum® Pro
- President & CEO Hawkins Jeffrey Alan sold $22,611 worth of shares (29,852 units at $0.76), decreasing direct ownership by 0.81% to 3,639,950 units (SEC Form 4) to satisfy withholding tax
- Chief Financial Officer Keyes Jeffry R. sold $5,806 worth of shares (7,665 units at $0.76), decreasing direct ownership by 0.44% to 1,716,684 units (SEC Form 4) (for tax liability)
- GC & Corp. Secretary Lapointe Christian sold $10,995 worth of shares (14,516 units at $0.76), decreasing direct ownership by 1% to 1,167,913 units (SEC Form 4) to satisfy tax liability
Latest TMO
- SEC Form 4 filed by Director Weisler Dion J
- SEC Form 4 filed by Director Sperling Scott M
- SEC Form 4 filed by Director Lynch Karen S
- SEC Form 4 filed by Director Johnson Jennifer M
- SEC Form 4 filed by Director Keith R. Alexandra
- Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 21, 2026
- Thermo Fisher Scientific Launches Gibco™ CHO-K1 Catalog Panel Media and Feed to Accelerate Biologics Development
- Thermo Fisher upgraded by UBS with a new price target
- CLSA initiated coverage on Thermo Fisher with a new price target
- Executive Vice President Shafer Michael D covered exercise/tax liability with 790 shares, decreasing direct ownership by 4% to 20,204 units (SEC Form 4)